Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 22 analyst ratings
Hold
Strong Buy 14%
Buy 27%
Hold 55%
Sell 5%
Strong Sell 0%

Bulls say

Amgen is a market leader in biotechnology-based therapeutics, with a diverse portfolio of flagship drugs including red blood cell boosters and immune system boosters. The company's recent acquisition of Onyx Pharmaceuticals has bolstered their oncology portfolio, and the 2023 acquisition of Horizon has brought in several rare-disease drugs. In addition, Amgen's biosimilar portfolio continues to grow. The company's recent earnings report beat expectations and raised guidance, and upgrades to their core portfolio drivers have led to a revised price target and outlook.

Bears say

Amgen is facing challenges with patent expirations and potential biosimilar competition, introducing uncertainty into its revenue stream. The upcoming catalysts, while promising, are several years away and present risks due to the long timeline and potential for any setbacks. This, combined with a high discount rate and low terminal growth rate in our DCF analysis, leads to our negative outlook for the stock.

Amgen (AMGN) has been analyzed by 22 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 27% recommend Buy, 55% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 22 analysts, Amgen (AMGN) has a Hold consensus rating as of Aug 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $392.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $392.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.